Revision History

As GLP-1 drugs like Ozempic and Mounjaro reach one in eight American adults, clinicians and researchers are raising concerns that patients with eating disorders — an estimated 30 million Americans — are obtaining these appetite-suppressing medications with little or no psychiatric screening. While evidence suggests GLP-1s may reduce binge eating episodes in some patients, the same drugs can reignite restrictive patterns in others, and no national guidelines require eating disorder screening before prescribing.